Add like
Add dislike
Add to saved papers

Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.

OBJECTIVES: T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a promising checkpoint. However, its features and prognostic value in lung adenocarcinoma remain undetermined. In this study, we aimed to characterize TIM-3 expression and its prognostic significance in patients with surgically resected lung adenocarcinoma.

MATERIALS AND METHODS: Expression of TIM-3 and programmed cell death 1 (PD-1), and density of CD8+ tumor infiltrating lymphocytes (TILs) were evaluated by immunohistochemistry in resected lung adenocarcinoma. The association between clinicopathological features or clinical outcomes and TIM-3 expression was analyzed.

RESULTS: A total of 223 patients were enrolled. TIM-3 expression was observed in 107 (48.0%) samples. Positive TIM-3 expression significantly correlated with positive PD-1 expression (p < 0.001) and high CD8+ TILs density (p = 0.014). TIM-3 positivity was significantly associated with worse recurrence-free survival (RFS) (hazard ratio [HR], 2.32; 95% confidence interval [CI], 1.44-3.73, p = 0.001) and overall survival (OS) (HR, 2.04; 95% CI, 1.29-3.20, p = 0.002). Subgroup analysis revealed that TIM-3+ /PD-1+ /CD8 low group had the worst RFS (5-year rate: 39.5%, p = 0.002) and OS (5-year rate: 50.0%, p = 0.035), while TIM-3- /PD-1- /CD8 high group had the best RFS (5-year rate: 93.8%, p = 0.002) and OS (5-year rate: 100%, p = 0.035).

CONCLUSION: TIM-3 had a relatively high positive expression rate and special clinicopathological features in patients with lung adenocarcinoma. A combination of TIM-3 and/or PD-1 expression or CD8+ TILs density could further stratify patients into different groups with distinct prognosis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app